Computational design enhances reactivity in artificial metallopeptides, suggesting efficiency for bioinorganic catalyst development.
Artificial metallopeptides hold immense potential to combine enzymatic activity with the versatility of organometallic catalysts. However, computational de novo design is largely limited to theozyme models that may neglect second-sphere atomic structure, overlook hydrogen-bonding networks, and ignore metal-induced conformational selection. We overcome these limitations by proposing a DFT-based bottom-up methodology applied to the design of Pd-binding (Met-X)ₙ sequences (X = Ala, Val, Ile). Line group symmetry theory is employed to accelerate the calculations by leveraging helical monoperiodicity for computational efficiency. Our DFT modeling reproduces the geometric parameters of α-poly-Ala with near-experimental accuracy, maps the α⟶π transition as a first-order phase transition, and identifies (Met-Ala)ₙ π-helices as the preferred matrices for canonical Pd(II) Suzuki coupling intermediates. In contrast, Pd incorporation in the α-helical matrix poses significant challenges, as shown by relaxed potential energy scans. From the periodic π-helix, we extract a cluster containing over 250 atoms and model it in aqueous solution at the ωB97X-V/def2-TZVP-gCP level to obtain reliable energetics for the free energy profile of the key oxidative addition step. The profile featured a low activation barrier and exergonic product formation, with reaction energy falling within the optimal window and barriers lower than those reported for bis-phosphine Pd(0) complexes. This methodology offers an efficient strategy for the de novo design of peptides and environmentally benign bioinorganic catalysts, from sequence to the reactivity of the metal center.
No takes yet. Share an insight, caveat, or question.
Domnin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: